Wound for Shire as Dermagraft fails in venous leg ulcers
This article was originally published in Scrip
Shire's newly acquired tissue regenerative product Dermagraft has failed in a Phase III study in venous leg ulcers, and will no longer be developed for this chronic wound indication.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.